206 related articles for article (PubMed ID: 24525285)
21. Proteasome inhibitors.
Teicher BA; Tomaszewski JE
Biochem Pharmacol; 2015 Jul; 96(1):1-9. PubMed ID: 25935605
[TBL] [Abstract][Full Text] [Related]
22. Proteasome inhibitor therapy for Waldenström's macroglobulinemia.
Dimopoulos MA; Terpos E; Kastritis E
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):235-7. PubMed ID: 23562304
[TBL] [Abstract][Full Text] [Related]
23. Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.
Manwani R; Mahmood S; Sachchithanantham S; Lachmann HJ; Gillmore JD; Yong K; Rabin N; Popat R; Kyriakou C; Worthington S; Sharpley F; Smith M; Shah R; Cheesman S; Hawkins PN; Wechalekar AD
Br J Haematol; 2019 Dec; 187(5):638-641. PubMed ID: 31388995
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy.
Meregalli C; Chiorazzi A; Carozzi VA; Canta A; Sala B; Colombo M; Oggioni N; Ceresa C; Foudah D; La Russa F; Miloso M; Nicolini G; Marmiroli P; Bennett DL; Cavaletti G
Cell Cycle; 2014; 13(4):612-21. PubMed ID: 24335344
[TBL] [Abstract][Full Text] [Related]
25. Toxic neuropathy.
Umapathi T; Chaudhry V
Curr Opin Neurol; 2005 Oct; 18(5):574-80. PubMed ID: 16155443
[TBL] [Abstract][Full Text] [Related]
26. Nonselective proteasome inhibitors in multiple myeloma and future perspectives.
Gavriatopoulou M; Malandrakis P; Ntanasis-Stathopoulos I; Dimopoulos MA
Expert Opin Pharmacother; 2022 Feb; 23(3):335-347. PubMed ID: 34761710
[TBL] [Abstract][Full Text] [Related]
27. The immunoproteasome as a therapeutic target for hematological malignancies.
Miller Z; Lee W; Kim KB
Curr Cancer Drug Targets; 2014; 14(6):537-48. PubMed ID: 25059201
[TBL] [Abstract][Full Text] [Related]
28. Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenström Macroglobulinemia.
Solia E; Dimopoulos MA; Kastritis E
Hematol Oncol Clin North Am; 2023 Aug; 37(4):689-705. PubMed ID: 37211495
[TBL] [Abstract][Full Text] [Related]
29. Tubulin binding potentially clears up Bortezomib and Carfilzomib differential neurotoxic effect.
Malacrida A; Semperboni S; Di Domizio A; Palmioli A; Broggi L; Airoldi C; Meregalli C; Cavaletti G; Nicolini G
Sci Rep; 2021 May; 11(1):10523. PubMed ID: 34006972
[TBL] [Abstract][Full Text] [Related]
30. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.
Lanzani F; Mattavelli L; Frigeni B; Rossini F; Cammarota S; Petrò D; Jann S; Cavaletti G
J Peripher Nerv Syst; 2008 Dec; 13(4):267-74. PubMed ID: 19192066
[TBL] [Abstract][Full Text] [Related]
31. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
32. Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
Bringhen S; Gay F; Donato F; Troia R; Mina R; Palumbo A
Expert Opin Investig Drugs; 2014 Sep; 23(9):1193-209. PubMed ID: 24905450
[TBL] [Abstract][Full Text] [Related]
33. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
Koeppen S
Oncol Res Treat; 2014; 37(9):506-13. PubMed ID: 25231692
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis
.
Hu B; Zhou Q; Wu T; Zhuang L; Yi L; Cao J; Yang X; Wang J
Int J Clin Pharmacol Ther; 2017 Apr; 55(4):329-338. PubMed ID: 28079515
[TBL] [Abstract][Full Text] [Related]
35. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
Kobrinsky B; Joseph SO; Muggia F; Liebes L; Beric A; Malankar A; Ivy P; Hochster H
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1073-8. PubMed ID: 24048674
[TBL] [Abstract][Full Text] [Related]
36. Carfilzomib for the treatment of multiple myeloma.
Lue J; Goel S; Mazumder A
Drugs Today (Barc); 2013 Mar; 49(3):171-9. PubMed ID: 23527321
[TBL] [Abstract][Full Text] [Related]
37. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
El-Cheikh J; Stoppa AM; Bouabdallah R; de Lavallade H; Coso D; de Collela JM; Auran-Schleinitz T; Gastaut JA; Blaise D; Mohty M
Clin Lymphoma Myeloma; 2008 Jun; 8(3):146-52. PubMed ID: 18650177
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.
Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A
High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):209-218. PubMed ID: 29582365
[TBL] [Abstract][Full Text] [Related]
39. Proteasome inhibitors for multiple myeloma.
Okazuka K; Ishida T
Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib-induced peripheral neurotoxicity in human multiple myeloma-bearing mice.
Meregalli C; Carozzi VA; Sala B; Chiorazzi A; Canta A; Oggioni N; Rodriguez-Menendez V; Ballarini E; Ceresa C; Nicolini G; Crippa L; Orciani M; Cavaletti G; Marmiroli P
J Biol Regul Homeost Agents; 2015; 29(1):115-24. PubMed ID: 25864747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
